

Survey: DS2/21  
month: May 2021  
Participant-No: 6426202  
date of issue: 22.05.21

Referenzinstitut für Bioanalytik

Labor Dr. Spranger  
Lindberghstr. 9 - 13  
85051 Ingolstadt



Survey directors

Prof. Dr. C. Knabbe  
Prof. Dr. Dr. K.P. Kohse  
Prof. Dr. M. Neumaier

Head of RfB

Dr. W. J. Geilenkeuser  
Dr. A. Kessler

## Certificate

### I. Screening (immunologic)

Correct findings were reported on the following:

- Amphetamine group
- Barbiturates
- Benzodiazepines
- Cannabinoids
- Cocain + metabolites
- Opiates

Bonn, 17. June 2021

**This certificate is according to the current version of the RiliBÄK valid until the end of November 2021.**

Survey: DS2/21  
month: May 2021  
Participant-No: 6426202  
date of issue: 22.05.21

Referenzinstitut für Bioanalytik

Labor Dr. Spranger  
Lindberghstr. 9 - 13  
85051 Ingolstadt



Survey directors

Prof. Dr. C. Knabbe  
Prof. Dr. Dr. K.P. Kohse  
Prof. Dr. M. Neumaier

Head of RfB

Dr. W. J. Geilenkeuser  
Dr. A. Kessler

## Participation certificate

We confirm that you have participated in the survey for drug screening.  
Your findings and the corresponding ratings were the following:  
(\* = correct, f = false, ? = missing, # = false positive)

Bonn, 17. June 2021

### I. Screening (immunologic)

	Sample A		Sample B	
	findings	rating	findings	rating
- Amphetamine group	-	●	+	●
- Barbiturates	-	●	+	●
- Benzodiazepines	+	●	+	●
- Cannabinoids	+	●	+	●
- Cocain + metabolites	+	●	-	●
- Opiates	-	●	-	●

*C. Knabbe*      *Dr. J. Geilenkeuser*      *A. Kessler*

0000 p038/ EPPNIC0236449022\_42\_112\_22 // 30076 \* 247 3330 17/31